Regimen provides ‘unprecedented’ PFS benefit in relapsed multiple myeloma

The addition of isatuximab-irfc to carfilzomib and dexamethasone conferred a durable PFS benefit to patients with relapsed multiple myeloma, according to updated results of the randomized phase 3 IKEMA trial.
“These results show an unprecedented median PFS of 3 years [among patients who received the three-agent regimen],” Philippe Moreau, MD, head of the department of hematology at University Hospital in Nantes, France, said during a presentation in an ESMO Virtual Plenary session. “That is the longest PFS observed using a proteasome inhibitor backbone in the relapsed

The addition of isatuximab-irfc to carfilzomib and dexamethasone conferred a durable PFS benefit to patients with relapsed multiple myeloma, according to updated results of the randomized phase 3 IKEMA trial.
“These results show an unprecedented median PFS of 3 years [among patients who received the three-agent regimen],” Philippe Moreau, MD, head of the department of hematology at University Hospital in Nantes, France, said during a presentation in an ESMO Virtual Plenary session. “That is the longest PFS observed using a proteasome inhibitor backbone in the relapsed